Wegovy ↔ Zepbound dose conversion
Equipotent dose mapping for patients considering a switch
Nearest-equipotent Zepbound (tirzepatide) dose
5.0 mg weekly
Editorial estimate based on comparative trial data (Wegovy (semaglutide) 1.0 mg weekly ↔ Zepbound (tirzepatide) 5.0 mg weekly). Not a clinical conversion table — prescribers typically re-titrate from a lower starting dose when switching between agents rather than substituting equipotent doses directly.
Educational only. Always discuss switching with your prescriber. Tirzepatide and semaglutide have different mechanisms (tirzepatide adds GIP agonism) so equipotent doses do not guarantee equivalent response or side-effect profile.
About this calculator
This is editorial guidance derived from comparative dose-response data in the STEP (semaglutide) and SURMOUNT (tirzepatide) trial programs. It is not a clinical conversion table. Tirzepatide's dual GLP-1/GIP agonism means even at equipotent semaglutide-equivalent doses, response and side-effect profiles can differ.
Standard prescribing practice when switching between these agents is to start the new agent at its lowest dose and titrate, not to substitute "equivalent" doses directly. See our Wegovy to Zepbound switching guide for the full protocol.